


PATENT SPECIFICATION

(11) 1350971

1350971

- (21) Application No. 14139/71 (22) Filed 11 May 1971
 (21) Application No. 396/72 (22) Filed 5 Jan. 1972
 (23) Complete Specification filed 21 April 1972
 (44) Complete Specification published 24 April 1974
 (51) International Classification C07C 61/06; A61K 27/00; C07C 101/44, 147/14, 149/30, 35/06, 49/28, 69/74 // C07D 5/32, 7/04; C07F 9/40, 9/54




- (52) Index at acceptance
 C2C 1175 1470 147X 1672 200 201 213 215 220 222
 225 226 227 22Y 231 246 247 24X 253 25Y
 26X 28X 292 29Y 304 30Y 311 313 314 31Y
 323 32Y 338 351 352 353 355 359 360 361 362
 364 365 366 367 368 36Y 373 37Y 388 389 38Y
 397 409 40Y 43X 491 500 502 503 504 509 50Y
 613 620 623 624 625 628 633 634 635 638 643
 644 652 655 658 65X 660 662 668 66X 672 67X
 680 694 697 699 761 767 774 779 790 79Y BJ
 BL BW LT LZ Q1 TU UF WD WP YV
 A5B 315 31Y 382 386 38Y 393 396 39X 421 422 424
 425 426 42Y 431 43Y 480 482 483 48Y 540 54Y
 565 56Y 586 58Y 595 59Y 606 60Y 644 645 646
 64X 64Y 654 655 656 65X 65Y 741 74Y
 C2P 1L1 1L2 2E12B 2E13 2E14 2E18B 2E18C 2E19C
 2E19D 2E19E 2E26A 2E26B 2E26D 3B12B 3B13
 3B14A 3B18B 3B18C 3B18D 3B19C 3B19D 3B19E
 3C12B 3C13 3C14 3C18B 3C18C 3C19C 3C19F
 3C30A 3C30B 7 8
 C3S 1C 1D 3A 3D 5 6 7B 7D 9
 (72). Inventors JEAN BOWLER and NEVILLE STANTON
 CROSSLEY

(54) CYCLOPENTANE DERIVATIVES

- (71) We, IMPERIAL CHEMICAL INDUSTRIES LIMITED, Imperial Chemical House, Millbank, London, SW1P 3JJ, a British Company, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—
- This invention relates to new cyclopentane derivatives, and in particular it relates to new cyclopentane derivatives which are analogues of the naturally occurring compounds known as prostaglandin $F_{2\alpha}$ and prostaglandin E_2 , showing a similar spectrum of pharmacological properties and being useful for similar purposes. The relative potency of the new compounds, however, in respect of the particular pharmacological effects shown is different from that of the above naturally occurring prostaglandins, and in particular they are more potent as luteolytic agents than the corresponding natural prostaglandins. That is to say, the prostaglandin $F_{2\alpha}$ analogues of the present invention are more potent than natural prostaglandin $F_{2\alpha}$, and the prostaglandin E_2 analogues of the present invention are more


potent than natural prostaglandin E_2 . The new compounds are, in a similar way, more potent as stimulants of uterine smooth muscle than the corresponding natural prostaglandins $F_{2\alpha}$ and E_2 , and the prostaglandin E_2 analogues of the invention are particularly valuable in this respect. The new compounds are therefore advantageous when used as contraceptives, for the termination of pregnancy or for control of the oestrus cycle, as hypotensives or for the relief of bronchospasm. The new compounds of the invention are also useful for addition to semen intended for artificial insemination of domestic animals, the success rate of insemination being thereby increased, especially in pigs.

The cyclopentane derivatives described in this specification will be named as derivatives of prostanoic acid of the formula shown below and numbered as shown:—



[Price 25p]

allyl or fluoroalkyl each of 1 to 4 carbon atoms or dimethylamino radicals.



Suitable halogen atom substituents in R¹ are, for example, chlorine, bromine or fluorine atoms. Suitable alkyl, alkoxy, alkenyl or alkenyloxy substituents of up to 4 carbon atoms in R¹ are, for example methyl, t-butyl, allyl, methoxy or allyloxy radicals. Suitable halogenoalkyl substituents of 1 to 4 carbon atoms in R¹ are, for example chloroalkyl or fluoroalkyl radicals, for example trifluoromethyl radicals. Suitable dialkylamino radicals wherein each alkyl is of 1 to 3 carbon atoms, which may be substituents in R¹ are, for example, dialkylamino radicals wherein the two alkyl radicals are the same, for example the diethylamino radical.

Suitable substituted aryl radicals are for example, chlorophenyl, chloronaphthyl, bromophenyl, fluorophenyl, tolyl, xylol, methyl-naphthyl, t-butylphenyl, methylchlorophenyl, trifluoromethylphenyl, hydroxyphenyl, methoxyphenyl, methoxynaphthyl, biphenyl, dimethylaminophenyl and tetrahydronaphthyl radicals.

Preferred aryl radicals contain not more than two substituents as defined above. Particular values for R⁴ are, therefore, the phenyl, benzyl, furfuryl, 1-naphthyl, 2-naphthyl, 2-, 3- and 4-chlorophenyl, 4-bromophenyl, 2-, 3- and 4-fluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dichlorophenyl, 2-, 3- and 4-tolyl, 2,3-, 3,4- and 3,5-xylyl, 4-t-butylphenyl, 3-allylphenyl, 3-trifluoromethylphenyl, 4-hydroxyphenyl, 2-, 3- and 4-methoxyphenyl, 4-biphenyl, 3-dimethylaminophenyl, 2-chloro-4-methylphenyl, 1-chloro-2-naphthyl, 4-chloro-2-naphthyl, 6-methyl-2-naphthyl, 6-methoxy-2-naphthyl and 5,6,7,8-tetrahydro-2-naphthyl radicals.

A suitable value for the alkyl radical of up to 4 carbon atoms which may be present as a substituent on carbon atom 2, 3 or 4 is, for example the methyl radical.

Examples of base-addition salts are the ammonium, alkyl-ammonium containing 1 to 4 alkyl radicals each of 1 to 6 carbon atoms, alkanolammonium containing 1 to 3 2-hydroxyethyl radicals, and alkali metal salts, for example the triethylammonium, ethanol-ammonium, diethanolammonium, sodium and potassium salts.

It will be observed that the compounds of the formula I contain at least five asymmetric carbon atoms, namely carbon atoms 8, 9, 11, 12 and 15, the configurations at four of which, 8, 9, 11 and 12 are specified in formula I, and that carbon atoms 2, 3 and 4 may also be asymmetrically substituted, so that it is clear that such compounds can exist in at least two optically active forms. It is to be understood that the useful properties of the racemate may be present to differing extents in the optical isomers, and that this invention relates

30 A suitable value for R¹ when it is an alkoxy-carbonyl radical of up to 11 carbon atoms is, for example, the methoxycarbonyl, ethoxycarbonyl, n-butoxycarbonyl or n-decyloxycarbonyl radical, preferably an alkoxy-carbonyl radical of up to 6 or 7 carbon atoms.

35 A suitable value for R^2 when it is an alkanoyloxy radical of 1 to 4 carbon atoms is, for example, the acetoxy or propionyloxy

A suitable value for X when it is an alkylene radical of 1 to 3 carbon atoms bearing as substituents 0, 1 or 2 alkyl radicals, each of 1 to 3 carbon atoms is, for example a methylene, ethylene or trimethylene radical bearing 0, 1 or 2 methyl substituents, for example the methylene, ethylidene, isopropylidene and trimethylene radicals.

A suitable value for Y when it is an alkylimino radical of up to 4 carbon atoms is, for example, the methylimino ($\text{CH}_3\text{—N}(\cdot)$) radical.

50 radical. A suitable value for A is the *trans*-vinylene radical.

55 radical. A suitable value for R^4 when it is an aryl radical optionally substituted, is for example a phenyl, naphthyl, or furfuryl benzyl radical optionally substituted by not than two halogen atoms, phenyl, hydroxy, methyl, t-butyl, allyl, methoxy, or allyloxy radicals, chloro-

to
for
the
and
of
to
pro

10 det
the
at
ste
sh

15 people
20 people

25

1
2
3
4

35

40

45

50

55

60

65

65 me:

to the racemic form of the compounds of formula I and any optically active form which shows the above useful properties, it being a matter of common general knowledge how the optically active forms may be obtained, and to determine their respective biological properties.

It is also to be understood that the above definition encompasses both C-15 epimers and that in all chemical formulae shown hereafter in this specification, the same fixed stereo-chemistry at C-8, 9, 11 and 12 as that shown in formula I is implied.

Although both C-15 epimers of a compound of the invention possess desirable pharmacological properties, that epimer which is more polar on thin layer chromatography is the more active, for example in the luteolytic test, and the more polar C-15 epimers are therefore preferred.


A preferred group of cyclopentane derivatives of the invention, because of their high luteolytic or smooth muscle stimulant properties, comprises those compounds wherein R^4 is a chlorophenyl, fluorephenyl, trifluoromethylphenyl or unsubstituted naphthyl radical, especially those compounds wherein R^1 is the carboxy, methoxycarbonyl or hydroxymethyl radical, and particularly those compounds wherein R^4 is the 3- or 4-chlorophenyl, 2- or 4-fluorophenyl, 3-trifluoromethylphenyl or unsubstituted naphthyl radical. A particularly preferred sub-group comprises those compounds wherein R^1 is the carboxy, methoxycarbonyl or hydroxymethyl radical, R^2 is the hydroxy radical and R^3 is a hydrogen atom, or R^2 and R^3 together form the oxo radical, A is the *trans*-vinylene radical, X is the methylene or isopropylidene radical, Y is an oxygen atom and R^4 is the 3- or 4-chlorophenyl, 2- or 4-fluorophenyl, 3-trifluoromethylphenyl or 2-naphthyl radical, optionally bearing a methyl substituent on carbon atom 2.

Particular preferred compounds of the invention are 16 - (4 - fluorophenoxy)- $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, methyl 16 - (4 - fluorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, 16 - (2 - fluorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, 16 - (4 - chlorophenoxy)- $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, methyl 16 - (4 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, 16 - (3 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, methyl 16 - (3 - chlorophenoxy) - $9\alpha,11\alpha,15$ -

trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, 16 - (3 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 2 - methyl-17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienol, $9\alpha,11\alpha,15$ - trihydroxy - 16 - (3 - trifluoromethylphenoxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, $9\alpha,11\alpha,15$ - trihydroxy - 16 - (2-naphthoxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, 16 - (4-chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy-16,16 - dimethyl - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid and 16 - (4 - chlorophenoxy) - $11\alpha,15$ - dihydroxy-9 - oxo - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid.


The cyclopentane derivatives of the invention may be manufactured by methods known in themselves for the manufacture of chemically analogous compounds. Thus, the following processes for the manufacture of the cyclopentane derivative of the formula I, are provided as further features of the invention:—

(a) for those compounds wherein R^1 is a carboxy radical, the hydrolysis of a compound of the formula:—



or of a mixed anhydride thereof, wherein A, X, Y, R^2 , R^3 and R^4 have the meanings stated above, and R^5 and R^6 are each a tetrahydropyran - 2 - yloxy radical, or an acyloxy radical of 1 to 6 carbon atoms, whereafter when a salt is required the product is reacted with a base; or

(b) for those compounds wherein R^1 is an alkoxycarbonyl radical of up to 11 carbon atoms, the reaction of an acid of the formula:—




wherein A, X, Y, R^2 , R^3 and R^4 have the meanings stated above, with a diazoalkane of the formula R^1N_2 , wherein R^1 is an alkyl radical of 1 to 10 carbon atoms; or

(c) for those compounds wherein R^1 is an alkoxycarbonyl radical of up to 11 carbon atoms, the reaction of a salt, for example the silver salt, of an acid of the formula III, with an alkyl halide of 1 to 10 carbon atoms, for example the alkyl iodide; or

(d) for those compounds wherein R^1 is the

hydroxymethyl radical and Y is the oxygen or sulphur atom, or an alkylimino radical, the reduction of an ester of the formula I wherein R¹ is an alkoxy-carbonyl radical, for example an alkoxy-carbonyl radical of up to 11 carbon atoms, for example with a complex metal hydride, for example lithium aluminium hydride, or

- (e) for those compounds wherein Y is the sulphinyl radical, the oxidation of a thio-compound of the formula:—



- wherein R¹, R², R³, R⁴, A and X have the meanings defined in claim 1, for example with sodium periodate.

- A suitable mixed anhydride is a mixed anhydride with a lower alkanolic acid, for example a lower alkanolic acid of up to 8 carbon atoms, for example acetic acid.

- The hydrolysis in process (a) may be carried out under either acidic or basic conditions, for example in aqueous acetic acid, or in an aqueous or alcoholic solution of an alkali metal carbonate, for example potassium carbonate in methanol, and it may be carried out at ambient temperature or at an elevated temperature of up to 60° C.

- The starting material of the formula II wherein A is a trans-vinylene radical, and Y is an oxygen or sulphur atom, used in the process of the invention may be obtained by reaction of the known aldehyde V (Ac = acetyl or *p*-phenylbenzoyl) with a phosphonate of the formula

- (CH₃O)₂P=O.-CH.CO.X.Y.R⁴

(which is prepared from dimethyl methylphosphonate and an ester of the formula



- in the presence of butyllithium), or with a phosphorane of the formula



(which is prepared from triphenylphosphine and a compound of the formula




to give an unsaturated ketone VI. The ketone VI is reduced with zinc borohydride to the corresponding unsaturated alcohol VII, and the protecting acyl group is then removed with potassium carbonate in methanol to give a diol VIII. The diol VIII is protected as a bis-tetrahydropyranyl ether and the lactone ring is then reduced with di-isobutyl aluminium hydride to give a lactol X, or alternatively the diol VIII is reduced with diisobutyl aluminium hydride to give a triol which may be acylated and selectively hydrolysed to give the lactol bis-ester (X, R³=R⁴=acyloxy). The lactol X is reacted with the phosphonium ylide anion obtained from (4-carboxybutyl)-triphenylphosphonium bromide and a strong base, to give a carboxylic acid of the formula II.

The starting material of the formula II wherein A is an ethylene radical, and Y is an oxygen or sulphur atom, used in the process of the invention, may be obtained by hydrogenating an unsaturated ketone VI in the presence of 5% palladium-on-carbon catalyst, or with nickel boride, to give a saturated ketone XI, and repeating the procedure outlined above using the saturated ketone XI in place of the unsaturated ketone VI.

The starting material of the formula II wherein R² is an alkanoyloxy radical may be obtained from the corresponding compound wherein R² is a hydroxy radical by acylation with an acid anhydride in pyridine to give a 9-ester-1-mixed anhydride.

The starting material of the formula II, III or IV wherein R² and R³ together form the oxo radical, may be obtained from the corresponding starting material of the formula II, wherein R² is hydroxy and R³ is hydrogen, by oxidation with Jones' reagent (chromic acid in ketone), followed, as required, by hydrolysis of the tetrahydropyranyl protecting groups and esterification of the carboxylic acid group.

It is, of course, to be understood that an optically active compound of the invention may be obtained either by resolving the corresponding racemate, or by carrying out the above-described reaction sequences starting from an optically active intermediate, for example from an optically active aldehyde of the formula IV (Ac = acetyl or *p*-phenylbenzoyl).



- 5 As stated above, the compounds of the invention possess a profile of pharmacological properties which differs from that of the naturally occurring prostaglandins $\text{F}_{2\alpha}$ and E_2 . Thus, for example, 16 - (4 - fluorophenoxyl) - 9 α ,11 α ,15 - trihydroxy - 17,18,19,20-tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid is approximately 200 times as active as prostaglandin $\text{F}_{2\alpha}$ in a luteolytic test in the hamster (oral dosing), and about 10 times the smooth muscle stimulant activity of prostaglandin $\text{F}_{2\alpha}$.

- Also as stated above, the compounds of the invention are useful, for example, for the induction of labour in childbirth, and for this purpose are used in the same way as it is known to use the naturally-occurring prostaglandins E_1 and E_2 , that is to say, by administering a sterile, substantially aqueous solution containing from 0.01 to 10 $\mu\text{g./ml.}$, preferably 0.01 to 1 $\mu\text{g./ml.}$ of active compound, by intravenous infusion until labour commences. Also, for this purpose, the compounds of the invention may be used in combination, or concurrently, with a uterine stimulant, for example oxytocin, in the same way that it is known to use prostaglandin $\text{F}_{2\alpha}$

in combination, or concurrently with oxytocin for the induction of labour.

When a compound of the invention is to be used for the control of the oestrus cycle in animals, it may be used in combination, or concurrently, with a gonadotrophin, for example PMSG (pregnant mare serum gonadotrophin) or HCG (human chorionic gonadotrophin) to hasten the onset of the next cycle.

Thus, according to a further feature of the invention there is provided a pharmaceutical or veterinary composition comprising a prostanoic acid derivative of the invention, together with a pharmaceutically or veterinarily acceptable diluent or carrier.

The compositions may be in a form suitable for oral administration, for example tablets or capsules, in a form suitable for inhalation, for example an aerosol or a solution suitable for spraying, in a form suitable for parenteral administration, for example sterile injectable aqueous or oily solutions or suspensions, or in the form of a suppository, suitable for anal or vaginal use. As stated above, when the compound of the invention is to be used for the induction of labour in childbirth, a preferred

composition of the invention is a sterile, substantially aqueous, injectable solution.

The compositions of the invention may be prepared by conventional means, and may incorporate conventional excipients.

The invention is illustrated, but not limited, by the following Examples:—

Example 1.

A solution of 9 α -hydroxy-16-phenoxyl-11 α ,15-bis(tetrahydropyran-2-yl)oxy)-17,18,19,20-tetranor-5-cis-13-trans-prostadienoic acid (120 mg.) in 1.5 ml. of 2:1 mixture of acetic acid and water, was stirred at 50° C. for 4 hours. The solvents were evaporated, the residue was dissolved in dilute aqueous sodium bicarbonate solution (2 ml.) and the solution was extracted with ethyl acetate (3 $\times$ 2 ml.) and the extracts were discarded. The aqueous solution was acidified to pH 3—4 with 2N aqueous oxalic acid and the acidified solution was extracted with ethyl acetate (4 $\times$ 5 ml.). The ethyl acetate extracts were washed with a 1:1 mixture of saturated brine and water, and were then dried. After evaporation of the ethyl acetate, the residue consisted of a mixture of the C-15 epimers of 9 α ,11 α ,15-trihydroxy-16-phenoxyl-17,18,19,20-tetranor-5-cis-13-trans-prostadienoic acid. Thin-layer chromatography on silica gel plates, supplied commercially by Merck of Darmstadt, using a mixture of benzene:dioxan:acetic acid (20:10:1) as the developing solvent, separated the C-15 epimers, having R_F values of 0.3 and 0.4, respectively. (Throughout this Example R_F values refer to silica gel plates supplied commercially by Merck of Darmstadt, and the spots were detected either by fluorescence, or by spraying the plates with a solution of ceric ammonium nitrate in sulphuric acid). The n.m.r. spectrum of each isomer (in deuterated acetone) showed the following characteristic bands (δ values):—

5.6—6.1, broad multiplet, 5 aromatic protons
4.2—4.8, broad multiplets, 4 olefinic protons
2.9—3.8, broad multiplets, 3H, H—C—O
and 4 exchangeable protons

The bis-tetrahydropyranyl ether used as starting material may be prepared as follows:—

n-Butyl lithium (69 ml. of a 1.2M solution in hexane) was added to a solution of dimethyl methylphosphonate (10.3 g.) in dry tetrahydrofuran at -78° C. in an atmosphere of nitrogen. After 10 minutes, a solution of phenoxyacetyl chloride (4.1 g.) in dry tetrahydrofuran (20 ml.) was added dropwise, and the mixture was stirred for 4 hours at -78° C. The reaction mixture was neutralised with acetic acid and the solvents were removed under reduced pressure. The residue was shaken with a mixture of ether (100 ml.) and

water (20 ml.), and the organic phase was separated and washed with brine. The solution was dried, the solvents were evaporated and the residue was distilled in a bulb distillation apparatus at an oven temperature of 160° C. and 0.1 mm. pressure, to give dimethyl 2-oxo-3-phenoxypylphosphonate.

A solution of dimethyl 2-oxo-3-phenoxypylphosphonate (1.01 g.) in dry 1,2-dimethoxyethane (20 ml.) at -78° C. was treated with n-butyl-lithium (2.75 ml. of a 1.2M solution in hexane), and the mixture was stirred for 15 minutes. To this mixture was added a solution of 4 β -formyl-2,3,3a β ,6a β -tetrahydro-2-oxo-5 α -(p-phenylbenzoyloxy)cyclopenteno[b]furan (1.95 g.) in 1,2-dimethoxyethane (10 ml.), and after 1 hour the reaction mixture was neutralised with glacial acetic acid and all solvents were removed by evaporation under reduced pressure below 35° C. The residue was chromatographed on "Florisil" (trade mark) silica using solutions of ethyl acetate in methylene chloride as eluant, to yield the unsaturated ketone product as a white solid. [R_F = 0.6 (1:1 ethyl acetate/benzene)].

To a solution of the unsaturated ketone (500 mg.) in dry 1,2-dimethoxyethane (20 ml.) at 0° C. was added 1.5 ml. of a 0.5 M solution of zinc borohydride in 1,2-dimethoxyethane. The mixture was stirred at room temperature for 30 minutes, then saturated sodium hydrogen tartrate solution was added until effervescence (10 ml.). 1N Hydrochloric acid (2.1 ml.) was added, the organic layer was separated, washed with a 1:1 mixture of saturated brine and water, then dried. The solvents were evaporated to give a mixture of epimeric unsaturated alcohols. [R_F = 0.3 (1:1 ethyl acetate/benzene)].

The mixture of epimeric unsaturated alcohols (500 mg.) was stirred vigorously for 2 hours with finely powdered anhydrous potassium carbonate (140 mg.) in methanol (10 ml.). 1N Hydrochloric acid (2.1 ml.) was added, followed by ethyl acetate (50 ml.). The organic layer was separated, washed successively with saturated sodium bicarbonate solution and saturated brine, and dried, and the solvents were evaporated. The residue was chromatographed on Florisil (20 g.). Elution with ether removed by-products, and subsequent elution with ethyl acetate gave a mixture of the C-15 epimeric diols [R_F = 0.2 (ethyl acetate)].

To a solution of the epimeric diols (316 mg.) in methylene chloride (3 ml.) under an atmosphere of nitrogen were added successively redistilled 2,3-dihydropyran (1.2 ml.) and a solution of anhydrous toluene-p-sulphonic acid in tetrahydrofuran (0.1 ml. of a 1% solution).

After 10 minutes, pyridine (3 drops) were added, followed by ethyl acetate (50 ml.). The solution was washed successively with

5 saturated sodium bicarbonate solution and saturated brine, and was dried. Evaporation of the solvents gave a mixture of epimeric bis-tetrahydropyranyl ethers as a clear oil. [$R_F = 0.6$ (ethyl acetate)].


10 To a solution of the epimeric bis-tetrahydropyranyl ethers (420 mg.) in dry toluene (10 ml.) under an atmosphere of nitrogen at -78°C . was added 1 ml. of a 2.2 mmole/ml. solution of di-isobutyl aluminium hydride in toluene. After 15 minutes the reaction was quenched by the dropwise addition of methanol (3 ml.) and after a further 15 minutes at room temperature a mixture of 15 1:1 saturated brine/water (25 ml.) was added, and the mixture was extracted with ethyl acetate (3×50 ml.). The extract was washed with saturated brine, and dried, and the solvents were evaporated to give a 20 mixture of epimers of 2,3,3a β ,6a β - tetrahydro - 2 - hydroxy - 4 β - [4 - phenoxy - 3 - (tetrahydropyran - 2 - yloxy) - 1 - *trans*-butenyl] - 5 α - (tetrahydropyran - 2 - yloxy)-cyclopenteno[b]furan. [$R_F = 0.4$ (1:1 ethyl acetate/benzene)].

25 Finely powdered (4-carboxybutyl)triphenylphosphonium bromide (1.11 g.) was heated to 100°C . under vacuum for 1 hour. The evacuated reaction vessel was filled with an atmosphere of dry nitrogen, the solid was dissolved in dimethylsulphoxide (5 ml.) and the solution was cooled to room temperature. To this solution was added dropwise 30 2.35 ml. of a 2M solution of methanesulphonylmethyl sodium in dimethyl sulphoxide followed by a solution of the mixture of epimers of the cyclopenteno[b]furan bis-tetrahydropyranyl ether (400 mg.) in a mixture of dimethyl sulphoxide (10 ml.) and 40 benzene (2 ml.). The solution was stirred for 3 hours, and the solvent was removed by evaporation under reduced pressure at a temperature below 40°C . The residue was

shaken with water (10 ml.) and ethyl acetate (10 ml.) and the aqueous phase was separated, 45 extracted with ethyl acetate (2×10 ml.) and the extracts discarded. The aqueous solution was acidified to pH 3—4 with 2N aqueous oxalic acid, and extracted with a mixture of 50 equal parts of ether and petroleum ether (b.p. $40-60^\circ\text{C}$.) (5×10 ml.). The organic phase was separated, washed with saturated brine and was dried. Evaporation of the solvents gave 9 α - hydroxy - 16 - phenoxy- 55 11 α ,15 - bis(tetrahydropyran - 2 - yloxy)-17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans*-prostadienoic acid as a clear oil. [$R_F = 0.5$ (ethyl acetate)].

Example 2.

The process described in Example 1 was 60 repeated, using the appropriate phosphonate reagent, to give the compounds shown below. The products were identified by n.m.r. spectroscopy and are characterised below 65 either by R_F value on thin layer chromatography, or by accurate mass measurement by mass spectrometry of either the molecular ion or the ($M^+ - \text{methyl}$) ion, whichever is 70 more appropriate, of the tetra (trimethylsilyl) derivative, which is prepared by adding to the compound to be mass measured bis-trimethylsilyl-trifluoroacetamide containing 1% trimethylchlorosilane (Regisil—trade mark) and 75 leaving the mixture for 1 hour. In some cases, phosphonate reagent, or the unsaturated ketone intermediate in which Ac is *p*-phenylbenzoyl have been characterised and appropriate data for these compounds are also given.



No.	R ₁	A	X
1	phenyl	—CH:CH—	—CH ₂ —
2	phenyl	—CH:CH—	—CH(CH ₃)—
3	phenyl	—CH:CH—	—C(CH ₃) ₂ —
4	phenyl	—CH:CH—	—(CH ₂) ₃ —
5	benzyl	—CH:CH—	—CH ₂ —
6	2-naphthyl	—CH:CH—	—CH ₂ —
7	4-chlorophenyl	—CH:CH—	—CH ₂ —
8	4-chlorophenyl	—CH ₂ CH ₂ —	—CH ₂ —
9	3-chlorophenyl	—CH:CH—	—CH ₂ —
10	2-chlorophenyl	—CH:CH—	—CH ₂ —
11	2,4-dichlorophenyl	—CH:CH—	—CH ₂ —
12	4-bromophenyl	—CH:CH—	—CH ₂ —
13	4-fluorophenyl	—CH:CH—	—CH ₂ —
14	4-tolyl	—CH:CH—	—CH ₂ —
15	3-tolyl	—CH:CH—	—CH ₂ —
16	4-t-butylphenyl	—CH:CH—	—CH ₂ —
17	3-trifluoromethylphenyl	—CH:CH—	—CH ₂ —
18	4-methoxyphenyl	—CH:CH—	—CH ₂ —
19	2-methoxyphenyl	—CH:CH—	—CH ₂ —
20	4-biphenyl	—CH:CH—	—CH ₂ —

No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

* mp :
 (a) F
 (b) R
 (c) R

No.	Isomer*	Mass spectrum		Phosphonate b.p. (°C./mm.)	Enone m.p. (°C.) (Formula VI)
		Found	Calculated		
1	mp lp	M ⁺ =678.3610 M ⁺ =678	678.3625	178—185/0.05	155—158
2	mp lp	M ⁺ —CH ₃ =677.3540 M ⁺ =692	677.3545 692	175/0.2	—
3	mixed	M ⁺ —CH ₃ =691.3660	691.3702	130/0.1	—
4	mp lp	M ⁺ =706.3921 M ⁺ =706	706.3928	166—168/0.1	120—122
5	mixed	M ⁺ =692.3753	692.3781	170/0.1	99—101
6	mp	M ⁺ =728.3744	728.3781	m.p.=85—86°C.	185—187
7	mp lp	M ⁺ —CH ₃ =697.2948 M ⁺ =712	697.3001 712	170—173/0.1	132—135
8	mp(a) lp(a)	M ⁺ =714.3399 M ⁺ =714	714.3391	170—173/0.1	132—135
9	mp lp	M ⁺ —CH ₃ =697.2297 M ⁺ =712	697.3000 712	180/0.2	—
10	mp lp	M ⁺ =712.3216 M ⁺ 712	712.3235	174—178/0.1	129—132
11	mp	M ⁺ —CH ₃ =731.2599	731.2609	—	136—138
12	mixed	M ⁺ —CH ₃ =741.2485	741.2497	—	—
13	mp lp	M ⁺ =696.3468 M ⁺ =696	696.3529	—	162
14	mixed	M ⁺ =692.3738	692.3781	164/0.05	149
15	mp lp	M ⁺ =692.3752 M ⁺ =692	692.3781	180/0.5	140—141
16	mixed	M ⁺ =734.4213	734.4251	—	—
17	mp lp	M ⁺ =746.3467(b) (c)	746.3499	—	115—117
18	mp lp	M ⁺ =708.3717 M ⁺ =708	708.3731	—	—
19	mp lp	M ⁺ =708.3710 M ⁺ =708	708.3731	—	—
20	mp lp	M ⁺ =754.3944 M ⁺ =754	754.3938	m.p.=63—64°C.	—

* mp=more polar, lp=less polar isomer on silica gel thin layer chromatography.

(a) products synthesised from respectively the more polar and less polar enol intermediates.

(b) R_F=0.45 after 2 runs on silica gel t.l.c. with 5% acetic acid in ethyl acetate.

(c) R_F=0.50 after 2 runs on silica gel t.l.c. as for (b).

In the manufacture of compounds 8, wherein A is an ethylene radical, the unsaturated ketone intermediate is reduced to the saturated ketone as follows:—

- 5 The more polar epimer (epimers at C-3 of the butenyl side-chain) of 4 β - (4 - *p* - chlorophenoxy - 3 - hydroxybut - 1 - *trans* - enyl) - 2,3,3a β ,6a β - tetrahydro - 2 - oxo - 5 α - (*p* - phenylbenzoyloxy)cyclopenteno - [b] -
- 10 furan (360 mg.) was dissolved in ethanol (25 ml.) and the solution was added to nickel boride, previously prepared from nickel acetate (620 mg.) and sodium borohydride (2.5 ml. of a 1 M solution). The mixture was shaken
- 15 with hydrogen for 3 hours and was then filtered, and the filtrate was evaporated to dryness to give 4 β - (4 - *p* - chlorophenoxy - 3 - hydroxybutyl) - 2,3,3a β ,6a β - tetrahydro - 2 - oxo - 5 α - (*p* - phenylbenzoyloxy)cyclo-
- 20 penteno[b] furan, $R_F = 0.4$ (50% ethyl acetate in toluene). The saturated ketone was then used, in place of the unsaturated ketone, in the remainder of the process described in Example 1.

25 Example 3.

- To a solution of the more polar C-15 epimer of 16 - (4 - chlorophenoxy) - 9 α ,11 α ,15-trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid (15 mg.) in
- 30 methanol (1 ml.) at 0° C. was added an excess of a solution of diazomethane in ether. After 10 minutes the solvents were evaporated to give a single C-15 epimer of methyl 16 - (4 - chlorophenoxy) - 9 α ,11 α ,15 - trihydroxy -
- 35 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate as a clear oil, $R_F = 0.3$ (ethyl

acetate). The n.m.r. spectrum showed the following characteristic bands (δ values):—

6.8—7.2, 4 aromatic protons
5.3—5.7, 4 olefinic protons
3.6, COOCH₃

40

Example 4.


The process described in Example 1 was repeated, using the appropriate phosphonate reagent, or an equivalent phosphorane R⁴—X—Y—CH₂.CO.CH: PPh₃ to give the compounds shown below. The products were identified by n.m.r. spectroscopy and are characterised below either by R_F value on thin layer chromatography, or by accurate mass measurement by mass spectrometry of the molecular ion of the appropriate fully protected (trimethylsilyl) derivative, which is prepared by adding, to the compound to be mass measured, bis - trimethylsilyltrifluoroacetamide containing 1% trimethylchlorosilane (Regisil-trade mark) and leaving the mixture for 1 hour. In some cases, the phosphonate reagent, or the unsaturated ketone intermediate have been characterised and appropriate data for these compounds are also given.

45

50

55

60



No

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

the

40

No.	R ⁴	X	Y	Other substituents in prostanoic acid
21	phenyl	—CH ₂ —	—N(CH ₃)—	—
22	4-chlorophenyl	—C(CH ₃) ₂ —	—O—	—
23	4-chlorophenyl	—CH ₂ —	—S—	—
24	3-fluorophenyl	—CH ₂ —	—O—	—
25	2-fluorophenyl	—CH ₂ —	—O—	—
26	3,4-dichlorophenyl	—CH ₂ —	—O—	—
27	2,5-dichlorophenyl	—CH ₂ —	—O—	—
28	2-tolyl	—CH ₂ —	—O—	—
29	2,3-xylyl	—CH ₂ —	—O—	—
30	3,5-xylyl	—CH ₂ —	—O—	—
31	2-chloro-4-methylphenyl	—CH ₂ —	—O—	—
32	3-dimethylaminophenyl	—CH ₂ —	—O—	—
33	1-naphthyl	—CH ₂ —	—O—	—
34	4-chloro-1-naphthyl	—CH ₂ —	—O—	—
35	2-naphthyl	—CH ₂ —	—O—	2-methyl
36	6-methyl-2-naphthyl	—CH ₂ —	—O—	—
37	6-methoxy-2-naphthyl	—CH ₂ —	—O—	—
38	3-chlorophenyl	—CH ₂ —	—O—	2-methyl
39	2,3-dichlorophenyl	—CH ₂ —	—O—	—
40	2,6-dichlorophenyl	—CH ₂ —	—O—	—
41	3,5-dichlorophenyl	—CH ₂ —	—O—	—
42	4-chloro-3-methylphenyl	—CH ₂ —	—O—	—
43	3-methoxyphenyl	—CH ₂ —	—O—	—
44	1-chloro-2-naphthyl	—CH ₂ —	—O—	—
45	5,6,7,8-tetrahydro-2-naphthyl	—CH ₂ —	—O—	—

was
non-
rane
the
were
are
on
mass
the
pro-
pre-
mass
nide
isil-
or 1
rent,
have
for

45

50

55

60

No.	Isomer (a)	Mass spectrum		Phosphonate b.p. (°C./mm.)	Enone m.p. (°C.) (Formula VI)*
		Found	Calculated		
40	mp lp	M ⁺ =746.2844 746	746.2844	m.p. 89—90	140—142
41	mp lp	M ⁺ =746.2829 746	746.2844	m.p. 80—82	138—139
42	mp lp	M ⁺ =726.3397 726	726.3391	—	143
43	mp lp	M ⁺ =708.3745 708	708.3730	(l)	129—130
44	mixed	M ⁺ =762.3402	762.3391	m.p. 61—62	195
45	mp(m) lp(n)				

(a) mp=more polar, lp=less polar.

(b) these compounds synthesised from phosphoranes (not phosphonates), made as described below.

(c) R_F=0.5 (50% ethyl acetate in toluene).

(d) R_F=0.2 (40% ethyl acetate in methylene dichloride)

(e) R_F=0.4 (5% acetic acid in ethyl acetate)

(f) R_F=0.3 (50% ethyl acetate in chloroform)

(g) R_F=0.23 (50% ethyl acetate in chloroform)

(h) R_F=0.3 (50% ethyl acetate in methylene dichloride)

(i) R_F=0.4 (10% methanol in ethyl acetate)

(j) R_F=0.8 (50% ethyl acetate in toluene)

(k) R_F=0.6 (50% ethyl acetate in toluene)

(l) R_F=0.4 (50% ethyl acetate in methylene dichloride)

(m) R_F=0.25 (3% acetic acid in ethyl acetate)

(n) R_F=0.30 (3% acetic acid in ethyl acetate)

(m) and (n); δ 6.8 (1H, aromatic), 6.6 (2H, aromatic), 5.4 (2H, olefinic) and 5.7 (2H, olefinic).

* Ac is *p*-phenylbenzoyl.

The preparation of a phosphorane, which may be used in place of a phosphonate in the preparation of a cyclopentane derivative of the invention, is exemplified by the preparation of [3 - (3 - dimethylaminophenoxy)-acetonilidene] - triphenylphosphorane as follows:—

- 5 n-Butyl-lithium (3.85 ml. of a 1.3 M solution in hexane) was added to a solution of 3-dimethylaminophenol (685 mg.) in dimethoxyethane (20 ml.) at -70° C. under an atmosphere of nitrogen. The solution was allowed to warm to room temperature, a solution of 3 - iodoacetonilidene - triphenylphosphorane (2.22 g.) in benzene (100 ml.) was added, and the mixture was heated under reflux for 2 hours. The mixture was then diluted with toluene (100 ml.), washed with water (2 × 50 ml.) and dried, the solvents were evaporated and the residue was triturated with ether to give [3 - (3 - dimethylamino-

phenoxy) acetonilidene] triphenylphosphorane, m.p. 110—115° C.

In a similar manner were prepared the analogous N-methylanilino (guin) and 4-chlorophenylthio (m.p. 158—165° C.) phosphoranes.

Example 5.

The process described in Example 3 was repeated, using the appropriate more polar C-15 epimer, in place of the more polar C-15 epimer of 16 - (4 - chlorophenoxy)-9 α ,11 α ,15 - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, to give the following methyl esters as single C-15 epimers:—

- a) methyl 16 - (4 - fluorophenoxy)-9 α ,11 α ,15 - trihydroxy - 17,18,19,20-tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, R_F = 0.3 (5% methanol in toluene) δ = 6.8—7.2 (aromatic), 5.3—5.7 (olefinic protons), 3.6 (methyl ester).

- b) methyl $9\alpha,11\alpha,15$ - trihydroxy - 16 - (2 - naphthyloxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, $M^+ = 670.3542$ (calculated 670.3541).
- 5 c) methyl $9\alpha,11\alpha,15$ - trihydroxy - 2 - methyl - 16 - (2 - naphthyloxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, $M^+ = 684.3678$ (calculated 684.3697).
- 10 d) methyl $9\alpha,11\alpha,15$ - trihydroxy - 16 - (6 - methyl - 2 - naphthyloxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, $M^+ = 684.3739$ (calculated 684.3698).
- 15 e) methyl $9\alpha,11\alpha,15$ - trihydroxy - 16 - (6 - methoxy - 2 - naphthyloxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, $M^+ = 700.3681$ (calculated 700.3647).
- 20 f) methyl 16 - (3 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, $R_F = 0.3$ (ethyl acetate), $M^+ = 654.2973$ (calculated 654.2995).
- 25 g) methyl $9\alpha,11\alpha,15$ - trihydroxy - 2 - methyl - 16 - (3 - chlorophenoxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, $R_F = 0.4$ (ethyl acetate), $M^+ = 668.3133$ (calculated 668.3151).
- 30

Example 6.

- 16 - (4 - Chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostanic acid (20 mg. of the more polar C-15 epimer) was treated with an excess of dilute aqueous ammonia to form the ammonium salt. The excess of ammonia was evaporated under reduced pressure, and the residue was treated with the stoichiometric amount of silver nitrate to form the silver salt. The silver salt was filtered off, dried, dissolved in *n*-butyl iodide (0.5 ml.) and stirred at room temperature for 1 hour. The solution was extracted with ethyl acetate, the ethyl acetate extract was evaporated to dryness, and the residue was chromatographed on Florisil (1 g.) using 50% ethyl acetate in toluene as eluant, to give *n*-butyl 16 - (4 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, M^+ for the tris-(trimethylsilyl) derivative = 696.3427 (calculated 696.3464), $R_F = 0.4$ (ethyl acetate).
- 45 In a similar manner, but using ethyl iodide in place of *n*-butyl iodide, there was obtained ethyl 16 - (4 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, $M^+ = 668.3086$ (calculated 668.3151).
- 50
- 55
- 60

Example 7.

A solution of the mixed anhydride of acetic acid and the more polar C-15 epimer of 9α - acetoxy - 16 - (4 - chlorophenoxy) -

11 α ,16 - bis(tetrahydropyran - 2 - yloxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid (73 mg.) in 2 ml. of a 2:1 mixture of acetic acid and water, was stirred at 47° C. under nitrogen for 4 hours. The solvents were evaporated, the residue was dissolved in dilute aqueous sodium bicarbonate solution (2 ml.) and the solution was extracted with ethyl acetate (3 $\times$ 2 ml.). The extracts were discarded, the aqueous solution was acidified to pH 3—4 with 2N aqueous oxalic acid and the acidified solution was extracted with ethyl acetate (4 $\times$ 5 ml.). The ethyl acetate extracts were washed with a 1:1 mixture of saturated brine and water, and were then dried. After evaporation of the ethyl acetate, the residue was purified by thin-layer chromatography on silica gel using 3% acetic acid in ethyl acetate, to give the more polar C-15 epimer of 9α - acetoxy - 16 - (4 - chlorophenoxy) - 11 α ,15 - dihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, $M^+ = 682.2942$ (calculated 682.2944).

The bis-tetrahydropyranyl ether used as starting material may be prepared as follows:—

A solution of the more polar C-15 epimer of 9α - hydroxy - 16 - (4 - chlorophenoxy) - 11 α ,15 - bis(tetrahydropyran - 2 - yloxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid (70 mg.) in 0.15 ml. of a 2:1 mixture of pyridine and acetic anhydride was kept at room temperature for 16 hours. The volatile material was evaporated and cyclohexane (10 ml.) was added to, and boiled off from, the residue three times, leaving the mixed anhydride of acetic acid and 9α - acetoxy - 16 - (4 - chlorophenoxy) - 11 α ,15 - bistetrahydropyran - 2 - yloxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid as a yellow oil, ν max (CHCl₃) 1720, 1810 cm⁻¹.

Example 8.

To a solution of 9α - acetoxy - 16 - (4 - chlorophenoxy) - 11 α ,15 - dihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid (12 mg.) in methanol (1 ml.) at 0° C. was added an excess of a solution of diazomethane in ether. After 10 minutes, the solvents were evaporated, the residue was dissolved in ether, and the solution was treated with lithium aluminium hydride (50 mg.). The mixture was stirred at room temperature for 1 hour, the excess of hydride was destroyed by the addition of water (1 ml.) and the mixture was extracted with ethyl acetate to give 16 - (4 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienol, $M^+ = 698.3439$ (calculated 698.3441), $R_F = 0.2$ (ethyl acetate).

In a similar manner, there were obtained:—
16 - (3 - chlorophenoxy) - $9\alpha,11\alpha,15$ - trihydroxy - 2 - methyl - 17,18,19,20 - tetra-

n.
R.
(
5 2
c.
(
10 re
re
a)
15
20
h.
25

oxy)-
trans- 65
2:1
The
was
carbon- 70
was
ml.).
uous
2N
ation 75
ml.).
with
water,
on of
ed by 80
using
the
-16-
oxy-
trans- 85
lated

d as
l as 90

dimer
α,15-
9,20-
enoic
ure of 95
ot at
lative
exane
from,
mixed 100
-16-
hydro-
anor-
as a
m⁻¹. 105

- (4-
oxy-
trans-
anol 110
of a
r 10
the
solu-
nium 115
ed at
ss of
n of
acted
loro- 120
oxy-
trans-
lated

d:— 125
- tri-
etra-

- nor - 5 - *cis* - 13 - *trans* - prostadienol,
R_F = 0.15 (ethyl acetate, M⁺ = 712.3575
(calculated 712.3597).
9α,11α,15 - trihydroxy - 16 - (6 - methyl-
5 2 - naphthyloxy) - 17,18,19,20 - tetranor - 5-
cis - 13 - *trans* - prostadienol, R_F = 0.2
(ethyl acetate).

Example 9.


- The process described in Example 1 was
10 repeated using the appropriate phosphonate
reagent, to give:—

- a) 9α,11α,15 - trihydroxy - 16 - (4-
hydroxyphenoxy) - 17,18,19,20 - tetranor-
5 - *cis* - 13 - *trans* - prostadienoic acid,
15 R_F = 0.2 and 0.3 (3% acetic acid in
ethyl acetate). δ = 6.82 (4H, aromatic),
5.3—5.7 (4H, olefinic), 3.98—5.1
20 (10H, >CH.O— and exchangeable pro-
tons); phosphonate, R_F = 0.2 (10%
methanol in ethyl acetate); enone*,
m.p. 135—140° C.
b) 16 - furfuryloxy - 9α,11α,15 - trihydroxy-
17,18,19,20 - tetranor - 5 - *cis* - 13-
25 *trans* - prostadienoic acid, R_F = 0.5 (3%
acetic acid in ethyl acetate), δ = 7.5

- (1H and 6.3 (2H) (furyl protons)
5.1—5.6 (4 H, olefinic); phosphonate,
b.p. 200° C./0.2 mm; enone*, m.p. 92—
93° C.
c) 16 - (3 - allylphenoxy) - 9α,11α,15- 30
trihydroxy - 17,18,19,20 - tetranor - 5-
cis - 13 - *trans* - prostadienoic acid,
M⁺ = 718.3892 (calculated 718.3938);
phosphonate, R_F = 0.32 (ethyl acetate);
enone*, m.p. 110—112° C. 35
* Formula VI. Ac is *p*-phenylbenzoyl.

Example 10

- The process described in Example 1 was
repeated, using a 9-oxo prostanoic acid deriva-
tive in place of a 9α-hydroxy prostanoic acid 40
derivative, to give the compounds shown
below. For measurement of mass spectra,
the acids were converted to methyl esters with
diazomethane, the 9-oxo group was protected
by conversion to the methoxime with 45
methoxylamine, and, where indicated, the
hydroxy groups at C-11 and C-15 were pro-
tected as the trimethylsilyl derivatives. N.m.r.
spectra were measured in deuterated acetone.



No.	R ⁴	X	Y
46	phenyl	—CH ₂ —	—O—
47	phenyl	—CH(CH ₃)—	—O—
48	phenyl	—(CH ₂) ₃ —	—O—
49	1-naphthyl	—CH ₂ —	—O—
50	2-naphthyl	—CH ₂ —	—O—
51	4-chlorophenyl	—CH ₂ —	—O—
52	4-chlorophenyl	—CH ₂ —	—S—
53	3-chlorophenyl	—CH ₂ —	—O—
54	2-chlorophenyl	—CH ₂ —	—O—
55	4-chlorophenyl	—C(CH ₃) ₂ —	—O—
56	4-bromophenyl	—CH ₂ —	—O—
57	4-fluorophenyl	—CH ₂ —	—O—
58	3-fluorophenyl	—CH ₂ —	—O—
59	2-fluorophenyl	—CH ₂ —	—O—
60	2,4-dichlorophenyl	—CH ₂ —	—O—
61	2,5-dichlorophenyl	—CH ₂ —	—O—
62	3,5-dichlorophenyl	—CH ₂ —	—O—
63	4-tolyl	—CH ₂ —	—O—
64	3-tolyl	—CH ₂ —	—O—
65	2-tolyl	—CH ₂ —	—O—
66	3,5-xylyl	—CH ₂ —	—O—
67	4-chloro-3-methyl-phenyl	—CH ₂ —	—O—
68	2-chloro-4-methyl-phenyl	—CH ₂ —	—O—
69	3-trifluoromethyl-phenyl	—CH ₂ —	—O—
70	4-methoxyphenyl	—CH ₂ —	—O—
71	2-methoxyphenyl	—CH ₂ —	—O—
72	4-chloro-1-naphthyl	—CH ₂ —	—O—

No.	Isomer*	Characterising Data
46	mixed	$R_F=0.2$ (acetone/cyclohexane/ethyl acetate—1:1:2) N.m.r.: δ 6.98—7.28 (5H, aromatic), 5.48 (2H, cis olefin), 5.78 (2H, trans olefin), 3.5—4.5 (5H, >CH.O— and —COOH)
47	mixed	$M^+=589.3267$ [calculated 589.3255 for methyl ester, 9-methoxime, 11,15-di-(trimethylsilyl) derivative]. $R_F=0.4$ (3% acetic acid in ethyl acetate)
48	mixed	$R_F=0.3$ (3% acetic acid in ethyl acetate)
49	mixed	$R_F=0.4$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 8.3—8.5 (1H), 7.7—7.9 (1H), 7.2—7.5 (4H) and 6.8—7.08 (1H)
50	mixed	$R_F=0.3$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.7—7.8 (3H) and 7.1—7.5 (4H)
51	mp	$M^+=609.2633$ [calculated 609.2709 for methyl ester, 9-methoxime, 11,15-di-(trimethylsilyl) derivative]. $R_F=0.4$ (3% acetic acid in ethyl acetate)
52	mixed	$R_F=0.5$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.3 (4H)
53	mp	$R_F=0.3$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.15 (1H) and 6.9 (3H)
54	mixed	$R_F=0.4$ (3% acetic acid in ethyl acetate).
55	mixed	$R_F=0.5$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.28 (2H), 7.19 (2H) and 2 methyls at δ 1.25 and 1.30 (6H)
56	mixed	$M^+=509.1417$ (calculated 509.1413 for methyl ester, 9-methoxime)
57	mixed	$R_F=0.3$ (3% acetic acid in ethyl acetate) N.m.r.: aromatic protons at δ 6.91 (2H) and 7.08 (2H)
58	mixed	$R_F=0.3$ (2% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.25 (1H) and 6.65 (3H)

No.	Isomer*	Characterising Data
59	mixed	$R_F=0.4$ (5% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.05 (4H)
60	mixed	$R_F=0.4$ (0.25% acetic acid in ethyl acetate) N.m.r.: aromatic protons at δ 7.12 (1H), 7.3 (1H) and 7.41 (1H)
61	mixed	$R_F=0.34$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.3 (1H), 7.15 (1H) and 6.9 (1H)
62	mixed	$R_F=0.34$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 6.9 (3H)
63	mixed	$R_F=0.2$ (cyclohexane/ethyl acetate/acetone, 2:2:1). N.m.r.: aromatic protons at δ 6.7 (2H) and 7.1 (2H), and methyl at δ 2.28
64	mixed	$R_F=0.5$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.05 (1H) and 6.73 (3H), and methyl at δ 2.28
65	mixed	$M^+=589.3284$ [calculated 589.3254 for methyl ester, methoxime, di (trimethylsilyl) derivative]. $R_F=0.35$ (3% acetic acid in ethyl acetate)
66	mixed	$R_F=0.2$ (cyclohexane/acetone/ethyl acetate—4:1:2). N.m.r.: aromatic protons at δ 6.5 (3H), and methyls (6H) at 2.28
67	mixed	$R_F=0.5$ (5% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.2 (1H) and 6.85 (2H), and methyl at 2.3
68	mixed	$R_F=0.4$ (cyclohexane/ethyl acetate/acetone—4:2:1). N.m.r.: aromatic protons at δ 7.18 (1H) and 6.80 (2H), and methyl at 2.2
69	mp	$R_F=0.5$ (5% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 7.5 (1H) and 7.25 (3H)
70	mixed	$R_F=0.6$ (3% acetic acid in ethyl acetate)
71	mixed	$R_F=0.65$ and 0.7 (3% acetic acid in ethyl acetate)
72	mixed	$R_F=0.4$ (3% acetic acid in ethyl acetate). N.m.r.: aromatic protons at δ 8.4 (1H), 8.15 (1H), 7.6 (3H) and 7.08 (1H)

* mp==more polar.

The 9-oxo prostanoic acid derivatives used as starting materials may be obtained by oxidation of the corresponding 9 α -hydroxy compound, as exemplified below for the preparation of 9-oxo-16-phenoxo-11 α ,15-bis(tetrahydropyran-2-yloxy)-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid:—

To a solution of 9 α -hydroxy-16-phenoxo-11 α ,15-bis(tetrahydropyran-2-yloxy)-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid (270 mg.) in acetone (5 ml.) at -10° C. was added Jones' reagent (chromic acid in acetone), 0.163 ml.). After 15 minutes, isopropanol (1 drop) was added, followed by ethyl acetate (20 ml). The solution was washed with 1:1 saturated brine/water, and was dried. Evaporation of the solvents, and chromatography of the residue on silica, using 1:1 ether/petroleum ether (b.p. 40–60° C.) as eluting solvent, gave the required 9-oxo-bis(tetrahydropyranyl ether), $R_F = 0.2$ (50% ethyl acetate in toluene).

Example 11.

The process described in Example 3 was repeated, using 11 α ,15-dihydroxy-16-(2-naphthylxy)-9-oxo-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid, in place of 16-(4-chlorophenoxo)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid, to give methyl 11 α ,15-dihydroxy-16-(2-naphthylxy)-9-oxo-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoate, $R_F = 0.3$ (ethyl acetate).

Example 12.

To a solution of 16-(4-chlorophenylthio)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid (12 mg.) in methanol (0.5 ml.) at 0° C. was added a solution of sodium periodate (5 mg.) in water (0.5 ml.). After 18 hours the solvents were evaporated, and the residue was extracted with acetone to give 16-(4-chlorophenylsulphonyl)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid, $M^+ = 744.2918$ (calculated 744.2956), $R_F = 0.2$ (3% acetic acid in ethyl acetate).

Example 13.

	% w/v
16-(4-fluorophenoxo)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5- <i>cis</i> -13- <i>trans</i> -prostadienoic acid	0.003
Sodium phosphate	2.90
Sodium hydrogen phosphate	0.30
Water for injection	to 100


The sodium phosphate was dissolved in about 80% of the water, followed by the prostadienoic acid derivative, and, when

dissolved, the sodium hydrogen phosphate. The solution was made up to volume with water for injection, and the pH was checked to be between 6.7 and 7.7. The solution was filtered to remove particulate matter, sterilised by filtration, and filled into presterilised neutral glass ampoules under aseptic conditions. Immediately before use, the contents of an ampoule are diluted in sodium chloride B.P. for administration by intravenous infusion.

The prostadienoic acid derivative may, of course, be replaced by an equivalent amount of another prostanoic acid derivative of the invention.

WHAT WE CLAIM IS:—

1. A prostanoic acid derivative of the formula:—



wherein R^1 is a hydroxymethyl or carboxy radical, or an alkoxycarbonyl radical of up to 11 carbon atoms; either R^2 is a hydroxy radical or an alkanoyloxy radical of 1 to 4 carbon atoms and R^3 is a hydrogen atom, or R^2 and R^3 together form the oxo radical; A is an ethylene or *trans*-vinylene radical; X is an alkylene radical of 1 to 3 carbon atoms bearing as substituents 0, 1 or 2 alkyl radicals, each of 1 to 3 carbon atoms; Y is an oxygen or sulphur atom, a sulphonyl ($-\text{SO}-$) radical or an alkylimino ($-\text{NAlkyl}-$) radical of up to 4 carbon atoms; and R^4 is an aryl, benzyl or furfuryl radical which is unsubstituted or which is substituted by halogen atoms, hydroxy, nitro or phenyl radicals, alkyl, alkenyl, halogenoalkyl, alkoxy, alkenyloxy or acylamino radicals of up to 4 carbon atoms or dialkylamino radicals wherein each alkyl is of 1 to 3 carbon atoms; which compound contains 0 or 1 alkyl radical of up to 4 carbon atoms on carbon atom 2, 3 or 4; and for those compounds wherein R^1 is a carboxy radical, the pharmaceutically acceptable salts thereof.

2. A prostanoic acid derivative as claimed in claim 1 wherein R^1 is a hydroxymethyl, carboxy, methoxycarbonyl, ethoxycarbonyl, *n*-butoxycarbonyl or *n*-decyloxycarbonyl radical; R^2 is a hydroxy, acetoxy or propionyloxy radical and R^3 is a hydrogen atom, or R^2 and R^3 together form the oxo radical; A has the meaning defined in claim 1; X is a methylene, ethylene or trimethylene radical bearing 0, 1 or 2 methyl substituents; Y is an oxygen or sulphur atom, or the sulphonyl or methylimino radical; and R^4 is a phenyl, naphthyl, benzyl or furfuryl radical containing as substituents not more than two halogen

The 9-oxo prostanoic acid derivatives used as starting materials may be obtained by oxidation of the corresponding 9- α -hydroxy compound, as exemplified below for the preparation of 9-oxo-16-phenoxy-11 α ,15-bis(tetrahydropyran-2-yloxy)-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid:—

To a solution of 9- α -hydroxy-16-phenoxy-11 α ,15-bis(tetrahydropyran-2-yloxy)-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid (270 mg.) in acetone (5 ml.) at -10°C . was added Jones' reagent (chromic acid in acetone), 0.163 ml.). After 15 minutes, isopropanol (1 drop) was added, followed by ethyl acetate (20 ml). The solution was washed with 1:1 saturated brine/water, and was dried. Evaporation of the solvents, and chromatography of the residue on silica, using 1:1 ether/petroleum ether (b.p. $40-60^{\circ}\text{C}$.) as eluting solvent, gave the required 9-oxo-bis(tetrahydropyranyl ether), $R_F = 0.2$ (50% ethyl acetate in toluene).

Example 11.

The process described in Example 3 was repeated, using 11 α ,15-dihydroxy-16-(2-naphthyl)-9-oxo-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid, in place of 16-(4-chlorophenoxy)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid, to give methyl 11 α ,15-dihydroxy-16-(2-naphthyl)-9-oxo-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoate, $R_F = 0.3$ (ethyl acetate).

Example 12.

To a solution of 16-(4-chlorophenylthio)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid (12 mg.) in methanol (0.5 ml.) at 0°C . was added a solution of sodium periodate (5 mg.) in water (0.5 ml.). After 18 hours the solvents were evaporated, and the residue was extracted with acetone to give 16-(4-chlorophenylsulphinyl)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5-*cis*-13-*trans*-prostadienoic acid, $M^+ = 744.2918$ (calculated 744.2956), $R_F = 0.2$ (3% acetic acid in ethyl acetate).

Example 13.

	% w/v
16-(4-fluorophenoxy)-9 α ,11 α ,15-trihydroxy-17,18,19,20-tetranor-5- <i>cis</i> -13- <i>trans</i> -prostadienoic acid	0.003
Sodium phosphate	2.90
Sodium hydrogen phosphate	0.30
Water for injection	to 100


The sodium phosphate was dissolved in about 80% of the water, followed by the prostadienoic acid derivative, and, when

dissolved, the sodium hydrogen phosphate. The solution was made up to volume with water for injection, and the pH was checked to be between 6.7 and 7.7. The solution was filtered to remove particulate matter, sterilised by filtration, and filled into presterilised neutral glass ampoules under aseptic conditions. Immediately before use, the contents of an ampoule are diluted in sodium chloride B.P. for administration by intravenous infusion.

The prostadienoic acid derivative may, of course, be replaced by an equivalent amount of another prostanoic acid derivative of the invention.

WHAT WE CLAIM IS:—

1. A prostanoic acid derivative of the formula:—



wherein R^1 is a hydroxymethyl or carboxy radical, or an alkoxycarbonyl radical of up to 11 carbon atoms; either R^2 is a hydroxy radical or an alkanoyloxy radical of 1 to 4 carbon atoms and R^3 is a hydrogen atom, or R^2 and R^3 together form the oxo radical; A is an ethylene or trans-vinylene radical; X is an alkylene radical of 1 to 3 carbon atoms bearing as substituents 0, 1 or 2 alkyl radicals, each of 1 to 3 carbon atoms; Y is an oxygen or sulphur atom, a sulphinyl ($-\text{SO}-$) radical or an alkylimino ($-\text{NAlkyl}-$) radical of up to 4 carbon atoms; and R^4 is an aryl, benzyl or furfuryl radical which is unsubstituted or which is substituted by halogen atoms, hydroxy, nitro or phenyl radicals, alkyl, alkenyl, halogenoalkyl, alkoxy, alkenyloxy or acylamino radicals of up to 4 carbon atoms or dialkylamino radicals wherein each alkyl is of 1 to 3 carbon atoms; which compound contains 0 or 1 alkyl radical of up to 4 carbon atoms on carbon atom 2, 3 or 4; and for those compounds wherein R^1 is a carboxy radical, the pharmaceutically acceptable salts thereof.

2. A prostanoic acid derivative as claimed in claim 1 wherein R^1 is a hydroxymethyl, carboxy, methoxycarbonyl, ethoxycarbonyl, n-butoxycarbonyl or n-decyloxycarbonyl radical; R^2 is a hydroxy, acetoxy or propionyloxy radical and R^3 is a hydrogen atom, or R^2 and R^3 together form the oxo radical; A has the meaning defined in claim 1; X is a methylene, ethylene or trimethylene radical bearing 0, 1 or 2 methyl substituents; Y is an oxygen or sulphur atom, or the sulphinyl or methylimino radical; and R^4 is a phenyl, naphthyl, benzyl or furfuryl radical containing as substituents not more than two halogen



atoms, phenyl, hydroxy, methyl, t-butyl, allyl, methoxy or allyloxy radicals, chloroalkyl or fluoroalkyl radicals each of 1 to 4 carbon atoms or dimethylamino radicals; which compound contains 0 or 1 alkyl radicals of up to 4 carbon atoms on carbon atom 2, 3 or 4; and for those compounds wherein R¹ is a carboxy radical the ammonium, alkyl-ammonium containing 1 to 4 alkyl radicals each of 1 to 6 carbon atoms, alkanolammonium containing 1 to 3 2-hydroxyethyl radicals, and alkali metal salts thereof.

3. A prostanoid acid derivative of the formula I shown in claim 1, wherein R¹ is a hydroxymethyl, carboxy, methoxycarbonyl, ethoxycarbonyl or n-butoxycarbonyl radical; R² is a hydroxy or acetoxy radical and R³ is a hydrogen atom, or R² and R³ together form the oxo radical; A is the ethylene or trans-vinylene radical; X is the methylene, ethylidene, isopropylidene or trimethylene radical; Y is an oxygen or sulphur atom, or the sulphinyl or methylimino radical; and R⁴ is the furfuryl or benzyl radical, or a phenyl or naphthyl radical containing as substituents not more than two chlorine, bromine or fluorine atoms, or phenyl, hydroxy, methyl, t-butyl, allyl, methoxy, trifluoromethyl or dimethylamino radicals; which compound optionally bears a methyl substituent on carbon atom 2.

4. A prostanoid acid derivative as claimed in any preceding claim wherein R⁴ is a chlorophenyl, chloronaphthyl, bromophenyl, fluorophenyl, tolyl, xylyl, methylnaphthyl, t-butylphenyl, methylchlorophenyl, trifluoromethylphenyl, hydroxyphenyl, methoxyphenyl, methoxynaphthyl, biphenyl, dimethylaminophenyl or tetrahydronaphthyl radical.

5. A prostanoid acid derivative as claimed in any preceding claim wherein R⁴ is the phenyl, benzyl, furfuryl, 1-naphthyl, 2-naphthyl, 2-, 3- or 4-chlorophenyl, 4-bromophenyl, 2-, 3- or 4-fluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2-, 3- or 4-tolyl, 2,3-, 3,4- or 3,5-xylyl, 4-t-butylphenyl, 3-allylphenyl, 3-trifluoromethylphenyl, 4-hydroxyphenyl, 2-, 3- or 4-methoxyphenyl, 4-biphenyl, 3-dimethylaminophenyl, 2-chloro-4-methylphenyl, 4-chloro-3-methylphenyl, 1-chloro-2-naphthyl, 4-chloro-2-naphthyl, 6-methyl-2-naphthyl, 6-methoxy-2-naphthyl or 5,6,7,8-tetrahydro-2-naphthyl radical.

6. A prostanoid acid derivative of the formula I shown in claim 1, wherein R¹ is a carboxy radical or an alkoxycarbonyl radical of up to 6 carbon atoms; either R² is a hydroxy radical or an alkanoyloxy radical of 1 to 4 carbon atoms and R³ is a hydrogen atom, or R² and R³ together form the oxo radical; A is an ethylene or trans-vinylene radical; X is an alkylene radical of 1 to 3 carbon atoms bearing as substituents 0, 1 or 2 alkyl radicals, each of 1 to 3 carbon atoms; and R⁴ is an aryl radical, which is unsubstituted

or which is substituted by halogen atoms, nitro radicals, alkyl, alkoxy or acylamino radicals of 1 to 4 carbon atoms or dialkylamino radicals wherein each alkyl is of 1 to 3 carbon atoms; and for those compounds wherein R¹ is a carboxy radical, pharmaceutically acceptable salts thereof.

7. A prostanoid acid derivative of the formula I given in claim 1 wherein R¹ is a hydroxymethyl or carboxy radical, or an alkoxycarbonyl radical of up to 7 carbon atoms; either R² is a hydroxy radical or an alkanoyloxy radical of 1 to 4 carbon atoms and R³ is a hydrogen atom, or R² and R³ together form the oxo radical; A is an ethylene or trans-vinylene radical; X is an alkylene radical of 1 to 3 carbon atoms bearing as substituents 0, 1 or 2 alkyl radicals, each of 1 to 3 carbon atoms; and R₄ is an aryl or benzyl radical, which is unsubstituted or which is substituted by halogen atoms, nitro or phenyl radicals, alkyl, halogenoalkyl, alkoxy or acylamino radicals of 1 to 4 carbon atoms or dialkylamino radicals wherein each alkyl is of 1 to 3 carbon atoms; and those compounds wherein R¹ is a carboxy radical, pharmaceutically acceptable salts thereof.

8. A prostanoid acid derivative as claimed in any one of claims 1, 2, 3, 6 and 7 wherein R⁴ is a chlorophenyl, fluorophenyl, trifluoromethyl or unsubstituted naphthyl radical.

9. A prostanoid acid derivative as claimed in any one of claims 1, 2, 3, 6 and 7 wherein R¹ is a carboxy or methoxycarbonyl radical and R⁴ is a chlorophenyl, fluorophenyl, trifluoromethyl or unsubstituted naphthyl radical.

10. A prostanoid acid derivative as claimed in any one of claims 1, 2, 3 and 7 wherein R¹ is the hydroxymethyl radical and R⁴ is a chlorophenyl, fluorophenyl, trifluoromethyl or unsubstituted naphthyl radical.

11. A prostanoid acid derivative as claimed in any one of claims 8, 9 and 10 wherein R⁴ is the 3- or 4-chlorophenyl, 2- or 4-fluorophenyl, 3-trifluoromethylphenyl or 2-naphthyl radical.

12. A prostanoid acid derivative of the formula I given in claim 1, wherein R¹ is the carboxy or methoxycarbonyl radical, R² is the hydroxy radical and R³ is a hydrogen atom or R² and R³ together form the oxo radical, A is the trans-vinylene radical, X is the methylene or isopropylidene radical, Y is an oxygen atom and R⁴ is the 3- or 4-chlorophenyl, 2- or 4-fluorophenyl, or 2-naphthyl radical.

13. A prostanoid acid derivative of the formula I given in claim 1 wherein R¹ is the carboxy, methoxycarbonyl or hydroxymethyl radical, R² is a hydroxy radical and R³ is a hydrogen atom, or R² and R³ together form the oxo radical, A is the trans-vinylene radical, X is the methylene or isopropylidene radical, Y is an oxygen atom and R⁴ is the 3-

or
tri

in
me

ox
ter

ac
90

hy
13

chl
17

pr
ph
17

pr
90

me
tri

tri
17

pr
ph
den
13

ox
ter

ac
den
3

ph
me
13

ph
17

pr
45

me
50

chl
55


pr
17

ac
den

pr
60


ns, nitro
radicals
no radi-
carbon
rein R¹
accept-
70
of the
R¹ is a
or an
75
atoms;
kanoyl-
and R²
together
or *trans*-
80
dical of
stituents
carbon
radical,
stituted
85
radicals,
ylamino
dialkyl-
of 1 to
where-
90
tically
claimed
wherein
fluoro-
95
ical.
claimed
wherein
radical
100
yl, tri-
radi-
claimed
wherein
105
R⁴ is
methyl
claimed
rein R⁴
-fluoro-
110
or 2-
of the
R¹ is
115
atom
radical,
is the
is an
120
chloro-
phthyl
of the
R¹ is
125
hydroxy-
al and
together
ethylene
lidene
the 3-
130

- or 4-chlorophenyl, 2- or 4-fluorophenyl, 3-trifluoromethylphenyl or 2-naphthyl radical.
14. A prostanoid acid derivative as claimed in claim 12 or 13 which additionally bears a methyl substituent on carbon atom 2.
15. The compounds 16 - (4 - fluorophenoxy) - 9 α ,11 α ,15 - trihydroxy - 17,18,19,20-tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, methyl 16 - (4 - fluorophenoxy)-9 α ,11 α ,15 - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoate, 16 - (2 - fluorophenoxy) - 9 α ,11 α ,15 - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, 16 - (4-chlorophenoxy) - 9 α ,11 α ,15 - trihydroxy-17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans*-prostadienoic acid, methyl 16 - (4 - chlorophenoxy) - 9 α ,11 α ,15 - trihydroxy-17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans*-prostadienoate, 16 - (3 - chlorophenoxy)-9 α ,11 α ,15 - trihydroxy - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid, methyl 16 - (3 - chlorophenoxy) - 9 α ,11 α ,15-trihydroxy - 17,18,19,20 - tetranor - 5 - *cis*-13 - *trans* - prostadienoate, 9 α ,11 α ,15-trihydroxy - 16 - (2 - naphthoxy)-17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans*-prostadienoic acid, and 16 - (4 - chlorophenoxy) - 9 α ,11 α ,15 - trihydroxy - 16,16-dimethyl - 17,18,19,20 - tetranor - 5 - *cis*-13 - *trans* - prostadienoic acid.
16. The compounds 16 - (4 - chlorophenoxy) - 9 α ,11 α ,15 - trihydroxy - 17,18,19,20-tetranor - 5 - *cis* - 13 - *trans* - prostadienol and 9 α ,11 α ,15 - trihydroxy - 16 - (3 - trifluoromethylphenoxy) - 17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans* - prostadienoic acid.
17. The compound 16 - (3 - chlorophenoxy) - 9 α ,11 α ,15 - trihydroxy - 2-methyl - 17,18,19,20 - tetranor - 5 - *cis*-13 - *trans* - prostadienol.
18. The compound 16 - (4 - chlorophenoxy) - 11 α ,15 - dihydroxy - 9 - oxo-17,18,19,20 - tetranor - 5 - *cis* - 13 - *trans*-prostadienoic acid.
19. A compound as claimed in any preceding claim which is the more polar of the C-15 epimers as shown by thin layer chromatography.
20. A compound as claimed in any preceding claim which is in a racemic form.
21. A compound as claimed in any one of claims 1 to 19 which is in a luteolytically effective, optically-active form.
22. A process for the manufacture of a prostanoid acid derivative as claimed in claim 1 which comprises:—
- (a) for those compounds wherein R¹ is a carboxy radical, the hydrolysis of a compound of the formula:—



or of a mixed anhydride thereof, wherein A, X, Y, R², R³ and R⁴ have the meanings stated above, and R⁵ and R⁶ are each a tetrahydropyran-2-yloxy radical, or an acyloxy radical of 1 to 6 carbon atoms, whereafter when a salt is required the product is reacted with a base; or

(b) for those compounds wherein R¹ is an alkoxycarbonyl radical of up to 11 carbon atoms, the reaction of an acid of the formula:—




wherein A, X, Y, R², R³ and R⁴ have the meanings stated above, with a diazoalkane of the formula R¹.N₂, wherein R¹ is an alkyl radical of 1 to 10 carbon atoms; or

(c) for those compounds wherein R¹ is an alkoxycarbonyl radical of up to 11 carbon atoms, the reaction of a salt of an acid of the formula II with an alkyl halide of 1 to 10 carbon atoms; or

(d) for those compounds wherein R¹ is the hydroxymethyl radical and Y is an oxygen or sulphur atom or an alkylsulfinio radical, the reduction of an ester of the formula I wherein R¹ is an alkoxycarbonyl radical of up to 11 carbon atoms; or

(e) for those compounds wherein Y is the sulphonyl radical, the oxidation of a thio-compound of the formula:—



wherein R¹, R², R³, R⁴, A and X have the meanings defined in claim 1.

23. A process as claimed in claim 22 wherein the hydrolysis is carried out in an aqueous or alcoholic solution of an alkali metal carbonate.

24. A process as claimed in claim 22 which

is carried out with a solution of potassium carbonate in methanol.

25. A process as claimed in claim 22 wherein the salt of an acid of the formula II is the silver salt.

26. A process as claimed in claim 22 wherein the alkyl halide is an alkyl iodide.

27. A process as claimed in claim 22 wherein the reduction is carried out with a complex metal hydride.

28. A process as claimed in claim 27 wherein the complex metal hydride is lithium aluminium hydride.

29. A process as claimed in claim 22 wherein the oxidation is carried out with sodium periodate.

30. A pharmaceutical or veterinary composition which comprises a prostanic acid derivative as claimed in claim 1 together with a pharmaceutically or veterinarily acceptable diluent or carrier.

31. A composition as claimed in claim 30 which is in a form suitable for oral administration, for inhalation, for parenteral administration, or for anal or vaginal use.

32. A composition as claimed in claim 31 which is a tablet, capsule, aerosol, solution suitable for spraying, sterile injectable aqueous or oily solution or suspension, or a suppository.

33. A composition as claimed in claim 30 which is a sterile, substantially aqueous solution containing from 0.01 to 10 $\mu\text{g./ml.}$ of the prostanic acid derivative.

34. A prostanic acid derivative as claimed in claim 1 substantially as hereinbefore described in any one of Examples 1 to 12.

35. A prostanic acid derivative as claimed in claim 6 substantially as hereinbefore described in Example 1.

36. A prostanic acid derivative as claimed in claim 7 substantially as hereinbefore described in any one of Examples 1 to 3.

37. A pharmaceutical or veterinary composition as claimed in claim 30 substantially as hereinbefore described in Example 13.

J. D. ATKINSON,
Agent for the Applicants.



ERRATA

SPECIFICATION No. 1,350,971

Page 2, line 37, *after propionyloxy insert radical.*

Page 2, line 54, *for or furfuryl benzyl read benzyl or furfuryl*

Page 2, line 58, *for allyl read alkyl*

Page 4, line 85, *for ketone) read acetone) for hydrolysis read hydrolysis*

Page 5, line 39, *for chlorionic read chorionic*

Page 6, line 94, *for stired read stirred*

Page 6, line 97, *delete whole line insert cence ceased. Ethyl acetate (100ml.) was*

Page 7, line 74, *after cases, insert the*

Page 11, Table No. 22 Headed R⁴ *for 4-chloropheny read 4-chlorophenyl*

Page 12, Table No. 37 3rd column *for*
M⁺ 758,3910 *read* M⁺ 758,3910
758 *758*

Page 13, Table No. 41 3rd column, *for*
M⁺ 746,2829 *read* M⁺ 746,2829
746 *746*

Page 14, line 92, *for chlorophenoxy read chlorophenoxy*

THE PATENT OFFICE
21st October, 1974

1350971